Home › Trial NCT05773040
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
- Trial IDNCT05773040
- StatusRecruiting
- PhasePhase 1
- Study typeInterventional
- SponsorM.D. Anderson Cancer Center
- Enrollment33
- Start date2023-04-14
- ConditionsLymphomas · B-cell Lymphomas
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.